SORT1 and pituitary gland adenoma: Furthermore, sortilin is significantly overexpressed in several cancers, including breast, colorectal, ovarian, pancreatic, melanoma and pituitary adenoma, highlighting its potential as a therapeutic target.[20] Compared to other LTRs, sortilin's efficient lysosomal transport capabilities and specific expression profile position it as a promising candidate for targeted therapies (Table S1, Supporting Information).